Your position:Home >Fuda News
  • Share
Fuda News

Latest News

More >>

Media report

No record right now.

More >>

Industry news

Xu Kecheng’s Lecture | Cryoablation Therapy for Renal Cancer

Malignant kidney tumors account for approximately 2%-3% of adult malignancies. In the urinary system, the incidence rate of kidney cancer is second only to bladder cancer, with renal cell carcinoma being the most common type. At the time of diagnosis, 20%-30% of patients already have metastases. For recurrent or stage IV and inoperable patients, radiotherapy and chemotherapy are ineffective, with a five-year survival rate of less than 10%. In recent years, ablation therapy has played an important role in the treatment of renal tumors, offering new treatment options for patients. Dr. Liang Bing, Vice President of Fuda Cancer Hospital in Guangzhou, shared insights on cryoablation therapy for kidney cancer...


Share Our WebSite
  • ——Share to——
  • Weibo
  • WeChat
  • QQ
  • FaceBook
  • Twitter
  • LinkedIn
  • Cancle
  • Contact Us
  • 24 hours line
  • Message